Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Consolidated Net Income: 2021-2025

Historic Consolidated Net Income for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $79.4 million.

  • Krystal Biotech's Consolidated Net Income rose 192.12% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 279.88%. This contributed to the annual value of $89.2 million for FY2024, which is 715.58% up from last year.
  • Latest data reveals that Krystal Biotech reported Consolidated Net Income of $79.4 million as of Q3 2025, which was up 107.05% from $38.3 million recorded in Q2 2025.
  • Krystal Biotech's Consolidated Net Income's 5-year high stood at $80.7 million during Q3 2023, with a 5-year trough of -$50.0 million in Q1 2022.
  • For the 3-year period, Krystal Biotech's Consolidated Net Income averaged around $21.9 million, with its median value being $27.2 million (2024).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 215.99% in 2022, then skyrocketed by 3,730.15% in 2025.
  • Quarterly analysis of 5 years shows Krystal Biotech's Consolidated Net Income stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then spiked by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then soared by 192.12% to $79.4 million in 2025.
  • Its Consolidated Net Income was $79.4 million in Q3 2025, compared to $38.3 million in Q2 2025 and $35.7 million in Q1 2025.